Ad5.F35-hGCC-PADRE vaccine

Ad5.F35-hGCC-PADRE is an academic cancer vaccine from Thomas Jefferson University targeting GUCY2C, a protein that sits on the surface of nearly all colorectal (~95% expression), the majority of gastric, esophageal, and small bowel adenocarcinomas, and a subset of pancreatic adenocarcinomas (expression rates vary by series), but is otherwise walled off inside the intestinal lumen in healthy tissue [1][2][8]. The Phase 2A trial (NCT04111172) tests a single dose of the adenoviral vaccine in patients with resected GI adenocarcinomas who are at high risk of recurrence, with immunogenicity and safety as anchor endpoints rather than survival [1]. A follow-on Phase 1 prime-boost regimen (NCT07417488) adds a Listeria-based boost (Lm-GUCY2C) to try to convert the vaccine's antibody-biased response into durable T-cell immunity, which is what actually matters for killing tumor cells [3]. Commercially this is early academic work with no partnered sponsor and no revenue, but the target itself is real estate that Takeda, Amgen, and multiple bispecific and CAR-T programs have tried to occupy [4][5].

Ad5.F35-hGCC-PADRE is a first-in-class investigational biologic with no approvals anywhere. The lead trial NCT04111172 is a Phase 2A dose-expansion study following a Phase 1 program that established tolerability and showed GUCY2C-specific antibody responses in the majority of vaccinated patients, with CD8 T-cell responses in a subset limited in part by pre-existing anti-Ad5 immunity, which is the exact problem the Ad5.F35 chimeric vector was engineered to bypass [1][6]. Specific response rates and dose levels are reported in the Snook/Waldman lab's Phase 1 publications [6]. No FDA designations (breakthrough, fast track, orphan, RMAT) have been publicly announced. The sponsor is Thomas Jefferson University's Waldman/Snook laboratory, not a commercial biotech, which means development pace is governed by academic grant cycles (NCI, DoD CDMRP) rather than a clinical operations team on quarterly milestones [1][6]. NCT04111172 has been open since 2019; current enrollment status and active site count are not publicly reported on ClinicalTrials.gov beyond 'recruiting' status, and the multi-year run-time is itself a signal of academic-pace execution. The newer prime-boost protocol NCT07417488 opened as a Phase 1 in advanced colorectal and small bowel adenocarcinoma (n=18) to determine a recommended Phase 2 dose for the Listeria boost, which resets the regulatory clock for the combination regimen [3]. Realistically, a pivotal registrational trial is not imminent; the near-term readouts will be immunogenicity data (antibody titers, tetramer-positive T cells) and disease-free survival signals from the adjuvant Phase 2A. Any move toward commercial partnership would likely happen only after a compelling recurrence-free survival delta in the resected-disease cohort.

GUCY2C, or guanylyl cyclase C, is normally a receptor stuck on the apical (lumen-facing) surface of intestinal cells. It listens for the gut peptides guanylin and uroguanylin, and when it binds them it makes cyclic GMP to regulate fluid balance. It is also the receptor that E. coli heat-stable enterotoxin hijacks to cause traveler's diarrhea [7]. The oncology angle is a quirk of anatomy: when an intestinal cell turns cancerous and breaks through the gut wall, GUCY2C goes along for the ride and ends up displayed on tumors throughout the body, but the healthy version stays locked behind the tight junctions of the gut lining where circulating T cells cannot reach it [2][8]. That compartmentalization is what makes GUCY2C an unusually clean tumor antigen: nearly every colorectal cancer expresses it, most gastric and small bowel adenocarcinomas do too, and pancreatic expression is reported in a subset (variable across studies). Immune attack on the antigen should not touch normal tissue as long as the gut barrier stays intact. Ad5.F35-hGCC-PADRE uses a chimeric adenovirus (Ad5 with an Ad35 fiber knob to sidestep pre-existing Ad5 immunity that is common in adults) to deliver the GUCY2C extracellular domain fused to PADRE, a synthetic universal T-helper epitope that recruits CD4 help to break tolerance against a self-antigen [6][8]. Genetic validation is strong; pharmacologic validation across the class is not yet, since Takeda's GUCY2C ADC (antibody-drug conjugate, an antibody engineered to deliver a cytotoxic payload directly to cancer cells) TAK-164 was discontinued after Phase 1 [4].

NCT04111172 is a single-arm, open-label Phase 2A in adults with stage I to III gastric, esophageal, pancreatic, small bowel, or colorectal adenocarcinoma who have completed standard curative-intent therapy and have no evidence of disease [1]. Patients receive a single intramuscular dose of Ad5.F35-hGCC-PADRE. Primary endpoints are safety and GUCY2C-specific immune response (antibody and T-cell), with disease-free survival as a secondary signal, not a registrational endpoint [1]. There is no comparator arm and no placebo, which is standard for an academic Phase 2A but means any efficacy read will need historical controls to interpret. The enrollment target per the published protocol is under 50 patients across the expansion cohorts (exact current enrollment is not publicly reported) [1]. The complementary NCT07417488 layers a Listeria monocytogenes-based Lm-GUCY2C boost onto the Ad5 prime in advanced colorectal and small bowel patients (n=18, Phase 1, dose-finding for the boost), with dose-limiting toxicity as the primary endpoint [3]. Neither study is designed to support approval on its own. The design's strength is a clean single-antigen readout in an adjuvant setting where micrometastatic disease should be most vulnerable to vaccine-induced T cells; the weakness is that immunogenicity endpoints do not reliably predict clinical benefit in cancer vaccines, as the graveyard of tumor-antigen vaccines from the 2000s and 2010s makes clear.

Our model estimates a 3% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by its light or open-label blinding; it is held back by the sponsor's thin or weak approval record, its few secondary endpoints, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the largest. Cancer vaccines against tumor-associated self-antigens have a long record of generating measurable immune responses that do not translate into survival benefit; sipuleucel-T is the exception, not the rule, and even it delivered a marginal median OS gain. The adjuvant setting improves the odds by attacking micrometastatic disease, but the trial has no comparator so any signal will be interpreted against historical DFS curves that vary widely by stage and tumor type. Safety risk is specific and non-trivial: GUCY2C is expressed on healthy intestinal epithelium, and although the tight-junction barrier should shield it from circulating T cells, breaking tolerance against a gut self-antigen carries a real risk of autoimmune enterocolitis. The published Phase 1 experience with the original Ad5-GUCY2C-PADRE construct did not report high-grade (Grade 3+) GI autoimmune adverse events, with reactogenicity limited primarily to injection-site reactions and low-grade constitutional symptoms; however, sample sizes were small (single-digit-per-cohort dose levels) and the Phase 2A larger cohort is where subclinical signals become clinical ones [6]. Execution risk is elevated because the sponsor is an academic center running two open trials in parallel on grant funding; enrollment pace across five tumor types at a small number of sites will be slow, and the pandemic-era protocol has already accumulated years of run-time. Commercial risk is severe even in a positive scenario: without a pharma partner, scaling adenoviral vaccine manufacturing (Ad5.F35 is not a standard commercial vector) and commercializing an adjuvant cancer vaccine into oncologist practice would require capital and a sales channel the university does not have.

Worth watching, not worth chasing. The target is genuinely interesting: GUCY2C is one of the cleanest tumor-restricted antigens in GI oncology by virtue of the gut barrier, and the modality choice (adenoviral prime with a Listeria boost and a PADRE helper epitope) is a serious attempt to solve the T-cell durability problem that has killed most tumor-antigen vaccines. But the vehicle here is an academic program on grant timelines with no commercial partner, competing in a target space where Takeda's ADC already failed and where Amgen's GUCY2C bispecific and other CAR-T efforts are still working through their own attrition [4][5]. The specific data point that would flip this from watchlist to actionable: a disease-free survival hazard ratio below 0.7 (meaning vaccinated patients relapse at least 30% less often than matched controls) in the resected-cancer adjuvant cohort of NCT04111172 versus a matched historical control, paired with polyfunctional GUCY2C-specific CD8 T-cell responses in more than half of vaccinated patients. Absent that, immunogenicity-only readouts are not investable. Because Thomas Jefferson University is an academic non-profit and does not file SEC disclosures, the real signals of commercial traction are: press releases from TJU's Office of Technology Commercialization or the Sidney Kimmel Cancer Center, a ClinicalTrials.gov sponsor field update from the university to a commercial entity, a spinout company formation announced through PR Newswire or BusinessWire, or a partnering deal disclosed via a licensee's SEC filings once one exists. Next check-in: monitor the Waldman/Snook lab's presentations at ASCO GI and SITC in 2027 for interim Phase 2A immunogenicity and safety data. Until any of the above triggers fires, the commercial signal is essentially zero and the score of 9.4% reflects that.